Last checked at 23 Mar 2023 07:00
hVIVO plc
("hVIVO" or the "Company")
Exercise of Options
hVIVO plc (AIM: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, confirms that it has issued 7,716,964 new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options by a former employee of the Company. It is expected that the admission of the Ordinary Shares will occur on 28 March 2023.
Following admission, the Company will have 678,764,735 Ordinary Shares in issue. This figure of 678,764,735 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
hVIVO plc | +44 (0) 20 7756 1300 | ||
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer | |||
Liberum Capital (Nominated Adviser and Joint Broker) | +44 (0) 20 3100 2000 | ||
Ben Cryer, Edward Mansfield, Phil Walker, Will King | |||
finnCap plc (Joint Broker) | +44 (0) 20 7220 0500 | ||
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM) | |||
Davy (Euronext Growth Adviser and Joint Broker) | +353 (0) 1 679 6363 | ||
Anthony Farrell, Niall Gilchrist | |||
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage /Louis Ashe-Jepson | +44 (0) 20 7933 8780 or hvivo@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /+44 (0) 7747 515 393 | ||
Notes to Editors
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.